Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)
- Admin
- Jun 9
- 2 min read
-- Non-dilutive funding supports next stage of clinical utility validation --
Los Angeles, CA – June 10, 2025 – Sensydia, a medical technology company advancing non-invasive cardiac assessment solutions, today announced the successful completion of Phase I milestones under its Fast-Track Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). As a result, Phase II funding has been activated to support clinical utility studies of the company's Cardiac Performance System (CPS™) in collaboration with University of Pittsburgh School of Medicine.
The multi-year, multi-phase grant, originally awarded in 2023 and totaling up to $3 million, provides Sensydia with non-dilutive funding for the development and clinical testing of the machine learning algorithms for CPS, designed to enable earlier detection and guidance of therapy for patients with heart failure and pulmonary hypertension.
“This continued NIH support reflects both the promise of our technology and the progress our team has made toward bringing CPS to patients,” said Aman Mahajan, MD, Chief Medical Officer of Sensydia and principal investigator of the NIH grant award.
The CPS platform uses proprietary non-invasive sensors and artificial intelligence algorithms to assess in real-time key hemodynamic parameters, providing clinicians with actionable data that traditionally requires invasive catheterization.
“This continued NIH support reflects both the promise of our technology and the progress our team has made toward bringing CPS to patients.” — Aman Mahajan, MD, Chief Medical Officer, Sensydia
This award builds on Sensydia’s recent momentum, including the initiation of its U.S. pivotal clinical study, enrollment of the first patient, and the addition of Rusty Page as President & COO.
About Sensydia
Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform that provides real-time measurements of critical cardiac function. CPS is designed to deliver rapid, safe, and accurate assessments to improve outcomes for patients with heart failure and pulmonary hypertension. The company received FDA 510(k) clearance for non-invasive measurement of ejection fraction using first-generation hardware in 2018. Learn more at sensydia.com.
Research reported in this announcement is supported by the NHLBI under Award Number 1R42HL167342-02. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Media contact:
Kathryn Morris, BrightPoint
914-204-6412
Comments